| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer S Giacchetti, B Perpoint, R Zidani, N Le Bail, R Faggiuolo, C Focan, ... Journal of clinical oncology 18 (1), 136-136, 2000 | 1847 | 2000 |
| Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study J Cortes, J O'Shaughnessy, D Loesch, JL Blum, LT Vahdat, K Petrakova, ... The Lancet 377 (9769), 914-923, 2011 | 1340 | 2011 |
| Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. D Machover, E Goldschmidt, P Chollet, G Metzger, J Zittoun, J Marquet, ... Journal of Clinical Oncology 4 (5), 685-696, 1986 | 470 | 1986 |
| Chronomodulated versus fixed-infusion—rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (Leucovorin) in patients with colorectal cancer … FA Lévi, R Zidani, JM Vannetzel, B Perpoint, C Focan, R Faggiuolo, ... JNCI: Journal of the National Cancer Institute 86 (21), 1608-1617, 1994 | 458 | 1994 |
| Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer M Bayet-Robert, F Kwiatowski, M Leheurteur, F Gachon, E Planchat, ... Cancer biology & therapy 9 (1), 8-14, 2010 | 452 | 2010 |
| Inflammatory breast cancer: pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate B Chevallier, H Roche, JP Olivier, P Chollet, P Hurteloup American journal of clinical oncology 16 (3), 223-228, 1993 | 420 | 1993 |
| Methionine dependency and cancer treatment E Cellarier, X Durando, MP Vasson, MC Farges, A Demiden, JC Maurizis, ... Cancer treatment reviews 29 (6), 489-499, 2003 | 314 | 2003 |
| Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate F Levi, B Perpoint, C Garufi, C Focan, P Chollet, P Depres-Brummer, ... European Journal of Cancer 29 (9), 1280-1284, 1993 | 253 | 1993 |
| Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer PF Innominato, C Focan, T Gorlia, T Moreau, C Garufi, J Waterhouse, ... Cancer research 69 (11), 4700-4707, 2009 | 232 | 2009 |
| Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2–overexpressing stage II or III … BP Coudert, R Largillier, L Arnould, P Chollet, M Campone, D Coeffic, ... Journal of clinical oncology 25 (19), 2678-2684, 2007 | 168 | 2007 |
| Phase II trial with S-1 in chemotherapy-naıve patients with gastric cancer. A trial performed by the EORTC early clinical studies group (ECSG) P Chollet, P Schöffski, K Weigang-Köhler, JHM Schellens, H Cure, ... European Journal of Cancer 39 (9), 1264-1270, 2003 | 165 | 2003 |
| Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy S Amat, F Penault-Llorca, H Cure, G Le Bouedëc, JL Achard, ... International journal of oncology 20 (4), 791-796, 2002 | 164 | 2002 |
| A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with … F Lévi, R Zidani, S Brienza, L Dogliotti, B Perpoint, M Rotarski, ... Cancer 85 (12), 2532-2540, 1999 | 164 | 1999 |
| Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer P Chollet, MA Bensmaine, S Brienza, C Deloche, H Cure, H Caillet, ... Annals of Oncology 7 (10), 1065-1070, 1996 | 164 | 1996 |
| Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. B Chevallier, P Chollet, Y Merrouche, H Roche, P Fumoleau, P Kerbrat, ... Journal of clinical oncology 13 (7), 1564-1571, 1995 | 160 | 1995 |
| Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome F Penault-Llorca, A Cayre, F Bouchet Mishellany, S Amat, V Feillel, ... International journal of oncology 22 (6), 1319-1325, 2003 | 151 | 2003 |
| The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study H Mahammedi, E Planchat, M Pouget, X Durando, H Curé, L Guy, ... Oncology 90 (2), 69-78, 2016 | 143 | 2016 |
| 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial X Pivot, G Romieu, M Debled, JY Pierga, P Kerbrat, T Bachelot, ... The Lancet 393 (10191), 2591-2598, 2019 | 142 | 2019 |
| Weight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse E Thivat, S Thérondel, O Lapirot, C Abrial, P Gimbergues, E Gadéa, ... BMC cancer 10, 1-9, 2010 | 142 | 2010 |
| High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer SC Abrial, F Penault-Llorca, R Delva, P Bougnoux, B Leduc, ... Breast cancer research and treatment 94, 255-263, 2005 | 140 | 2005 |
